Edesa Biotech is trading at $3.25, up +51.87%, after a Japan licensing agreement with Kyorin.
- The November 9 agreement grants Kyorin exclusive Japan rights to develop and commercialize paridiprubart for ARDS.
- The deal includes $12 million upfront, up to $134 million in potential milestones and royalties; Kyorin will fund Japanese development.
- Shares closed at $2.14 on November 6; no live volume figure was provided.